Integrated Solutions for Biomarker Discovery

Personalizing medicine by targeting tumors for treatment will be helped by identifying new biomarkers. Biomarkers indicate a disease or outcome, often because they are involved in the biological mechanism. Variants or mutations, in biomarker genes, can impact disease risk, affect a subject’s response to treatment, or lead to genetic dysregulation that results in disease. The development of cutting-edge technologies has advanced the identification of cancer biomarker. Most cancer biomarker studies are focused on individual genetic variables, transcriptome alterations, and impaired protein function as distinct risk and prognostic factors. These single streamlined approaches for biomarker discovery can be valuable for the available analytical methods, which assess genomic, transcriptome, or protein composition separately.

Fig.1 Integration of genomic, epigenetic, transcriptomic, and proteomic data for comprehensive analysis of cell dynamics through multi-omics. (Hristova & Chan, 2019 )

Research in the discovery and identification of new, targetable biomarkers is driven by comprehensive tumor profiling. Molecular characterization of tumor types can identify biomarkers through comprehensive tumor profiling. When matched normal and tumor samples are compared, tumor-specific mutations and their functions can be identified. Creative Biolabs offers next-generation sequencing (NGS), in situ hybridization (ISH), polymerase chain reaction (PCR), immunohistochemistry (IHC), and microarray-based tumor profiling to facilitate the process of biomarker discovery.

Biomarker Discovery Service at Creative Biolabs

The most comprehensive technology for tumor profiling is NGS. However, due to the low quantity and quality of DNA in tissue samples, converting tissue samples into NGS libraries is often challenging. converting tissue samples into NGS libraries is often challenging due to the low quantity and quality of DNA in such samples. Here, we present confident and accurate identification of low-frequency variants by optimized library construction for low-input and degraded samples. In our workflow, a single-stranded ligation strategy was used to maximize conversion and effectively eliminate adapter-dimer formation and reduces chimera rates. Scientists at Creative Biolabs are proficient at identifying tumor-associated variants in both matched formalin-fixed, paraffin-embedded (FFPE), and cell-free DNA (cfDNA) samples.

Fig.2 Technologies for tumor profiling, which can be used for biomarker discovery. (Creative Biolabs)

Moreover, the variability and limited clinical efficacy of current cancer biomarkers is possibly due to the lack of functional relevance of biomarker genes to cancer progression. To address this challenge, Creative Biolabs has developed a biomarker discovery pipeline to integrate gene expression profiles and essential survival gene datasets. By applying this pipeline, tumor progression-related genes have been identified in several cancers.

Advantages of Our Service

• Improved the sensitivity and high throughput
• Detection and quantification of low-frequency genomic alterations
• Emphasizing the high degree of heterogeneity reported within tumors
• Analyzing the compound effect of multiple mutations on disease onset and progression

Except for tumor profiling, we are pleased to introduce our integrated solutions for biomarker discovery, which include MS-based profiling, proteomics, peptidomics, epigenetics, cancer-biomarker-family approach, secreted protein approach and other advanced strategies. Creative Biolabs accommodates everything from project design for biomarker discovery to validated assays. For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

1. Hristova, V.A.; Chan, D.W. Cancer biomarker discovery and translation: proteomics and beyond. Expert review of proteomics. 2019, 16(2): 93-103.

For Research Use Only | Not For Clinical Use